Jitka Soukupová
The discovery of a novel antimetastatic Bcl3 inhibitor
Soukupová, Jitka; Bordoni, Cinzia; Turnham, Daniel J.; Yang, William W.; Seaton, Gillian; Gruca, Aleksandra; French, Rhiannon; Lee, Kok Yung; Varnava, Athina; Piggott, Luke; Clarkson, Richard W.E.; Westwell, Andrew D.; Brancale, Andrea
Authors
Cinzia Bordoni
Daniel J. Turnham
William W. Yang
Gillian Seaton
Aleksandra Gruca
Rhiannon French
Kok Yung Lee
Athina Varnava
Luke Piggott
Richard W.E. Clarkson
Andrew D. Westwell
Andrea Brancale
Abstract
The development of antimetastatic drugs is an urgent healthcare priority for patients with cancer, because metastasis is thought to account for around 90% of cancer deaths. Current antimetastatic treatment options are limited and often associated with poor long-term survival and systemic toxicities. Bcl3, a facilitator protein of the NF-κB family, is associated with poor prognosis in a range of tumor types. Bcl3 has been directly implicated in the metastasis of tumor cells, yet is well tolerated when constitutively deleted in murine models, making it a promising therapeutic target. Here, we describe the identification and characterization of the first small-molecule Bcl3 inhibitor, by using a virtual drug design and screening approach against a computational model of the Bcl3-NF-kB1(p50) protein–protein interaction. From selected virtual screening hits, one compound (JS6) showed potent intracellular Bcl3-inhibitory activity. JS6 treatment led to reductions in Bcl3-NF-kB1 binding, tumor colony formation, and cancer cell migration in vitro; and tumor stasis and antimetastatic activity in vivo, while being devoid of overt systemic toxicity. These results represent a successful application of in silico screening in the identification of protein–protein inhibitors for novel intracellular targets, and confirm Bcl3 as a potential antimetastatic target.
Journal Article Type | Article |
---|---|
Acceptance Date | Feb 24, 2021 |
Online Publication Date | Mar 1, 2021 |
Publication Date | May 1, 2021 |
Deposit Date | Oct 22, 2024 |
Publicly Available Date | Oct 29, 2024 |
Journal | Molecular Cancer Therapeutics |
Print ISSN | 1535-7163 |
Electronic ISSN | 1538-8514 |
Publisher | American Association for Cancer Research |
Peer Reviewed | Peer Reviewed |
Volume | 20 |
Issue | 5 |
Pages | 775-786 |
DOI | https://doi.org/10.1158/1535-7163.mct-20-0283 |
Public URL | https://uwe-repository.worktribe.com/output/13307554 |
Files
The discovery of a novel antimetastatic Bcl3 inhibitor
(7.3 Mb)
PDF
Licence
http://www.rioxx.net/licenses/all-rights-reserved
Copyright Statement
This is the author's accepted manuscript. The final published version is available here: https://doi.org/10.1158/1535-7163.MCT-20-0283.
You might also like
PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate
(2023)
Journal Article
Downloadable Citations
About UWE Bristol Research Repository
Administrator e-mail: repository@uwe.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search